Last reviewed · How we verify
NCT05087277
Correlation Study of Isotype Switching and Neutralizing Capacity to the COVID-19 Variants Strain
trial in COVID-19 in 150 participants. Status unknown.
10 October 2021
Quick facts
| Lead sponsor | Centers for Disease Control and Prevention, China |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 20 July 2020 |
| Primary completion | 10 October 2021 |
| Estimated completion | 30 October 2021 |
| Sites | 1 location across China |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Centers for Disease Control and Prevention, China — full company profile →
Who can join
Adults 18 to 59, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The level of neutralizing antibody was detected by using the constructed pseudovirus covid-19 variant at baseline , 1 month , 6 months and 12 months after primary vaccination, within 15 days after booster immunization at 12 months . and the ability of IgG subclasses to neutralize and cross immunization of variant strains was analyzed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05087277
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Centers for Disease Control and Prevention, China trials
Trials by the same sponsor.
- NCT05298800 — Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 · Phase 4 · unknown
- NCT04614597 — A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China · completed
- NCT05072496 — Study on Antibody Persistence and Immune Memory of Inactivated COVID-19 Vaccine · completed
- NCT03597919 — A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China. · Phase 4 · completed
- NCT03546634 — Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05087277 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centers for Disease Control and Prevention, China
- Last refreshed: 21 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05087277.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing